Close Menu

NEW YORK – Quest Diagnostics received on Tuesday Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.

The issuance allows Quest to provide the test for individuals suspected by their healthcare providers of having COVID-19.

On Saturday, the company said that between the capacity provided by its own test as well as other authorized in vitro diagnostic SARS-CoV-2 test kits, it expected to be able to perform roughly 10,000 tests a day by the end of this week and roughly 20,000 tests per day by the end of March.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.